Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs  by Antman, Elliott M. et al.
698 JACC Vol. 15, No. 3 
March 1, 1990:698-707 
Therapy of Refractory Symptomatic Atria1 Fibrillation and Atria1 
Flutter: A Staged Care Approach With New Antiarrhythmic Drugs 
ELLIOTT M. ANTMAN, MD, ANDREW D. BEAMER, MD, CATHERINE CANTILLON, RN, 
NOREEN MCGOWAN, RN, PETER L. FRIEDMAN, MD, PHD 
Boston, Massachusetts 
One hundred nine patients with recurrent episodes of 
symptomatic atria1 fibrillation or flutter, or both, who had 
failed one to five previous antiarrhythmic drug trials were 
treated with propafenone and, subsequently, sotalol if 
atrial fibrillation recurred. The clinical profile of the study 
group was as follows: age 63 f 13 years, left atriat 
anteroposterior dimension 4.4 f 0.9 cm and left ventricular 
ejection fraction 57 2 14%. Paroxysmal atrial fibrillation 
occurred in 56 patients (51%) and chronic atrial fibrillation 
occurred in 53 patients (49%). 
After loading and dose titration phases were completed, 
the maintenance doses of drugs were 450 to 900 mg/day for 
propafenone and 160 to 960 mg/day for sotalol. Life table 
estimates of the duration of freedom from atrial fibrillation 
were constructed for each drug trial. The percent of 
Atria1 fibrillation, an extremely common cardiac arrhythmia, 
is estimated to affect 2% to 4% of adults >60 years of age 
(1,2). Conventional antiarrhythmic drugs (quinidine, pro- 
cainamide and disopyramide) are widely prescribed to pre- 
vent recurrence of atrial fibrillation, even though the relative 
benefits of treatment with such agents have never been 
substantiated in large scale randomized clinical trials. Be- 
cause these agents often fail to prevent recurrence of atria1 
fibrillation or frequently must be discontinued because of 
intolerable drug-related side effects, attention has focused on 
the use of alternative agents in the management of patients 
with atria1 fibrillation or flutter. Among the newer antiar- 
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patients free of recurrent symptomatic arrhythmia at 6 
months was 39% for propafenone and 50% for sotalol. The 
cumulative proportion of patients successfully treated with 
propafenone or sotalol, or both, by 6 months was 55% and 
remained relatively constant beyond that point. The inci- 
dence of intolerable side effects necessitating discontinua- 
tion of therapy ranged from 7% to 8% 
Thus, despite previous unsuccessful drug trials, a sub- 
stantial proportion of patients with recurrent symptomatic 
atria1 fibrillation refractory to conventional therapy can be 
treated successfully and safely with newer antiarrhythmic 
drugs. Treatment failures tend to occur early in the course 
of follow-up, permitting easy identification of candidates 
for alternative therapeutic approaches. 
(J Am Co11 Cardiol1990;15:698-707) 
rhythmic agents, compounds that markedly slow conduction 
in the atria1 myocardium (class IC drugs) and prolong the 
effective refractory period of atria1 myocardial cells (class III 
drugs) have electrophysiologic profiles suggesting that they 
would be potent antifibrillatory agents. Previously published 
studies with agents such as propafenone (3-7) and sotalol 
(8-10) have reported favorable clinical results. However, 
limited data are available on the long-term effectiveness of 
such drugs. Detailed clinical investigations have not been 
carried out to evaluate these new antiarrhythmic agents 
alone or in combination for patients with recurrent sympto- 
matic atria1 fibrillation. 
The objective of this study was to examine the efficacy 
and safety of sequential antiarrhythmic drug trials with 
propafenone and sotalol for the long-term suppression of 
recurrent symptomatic atria1 fibrillation or flutter, or both, 
that was inadequately treated by conventional type IA 
antiarrhythmic drugs. The protocol was designed to simulate 
clinical practice and consisted of a series of two drug trials 
using the technique of upward titration of antiarrhythmic 
dosage after recurrence of atria1 fibrillation. A previous 
report (3) from our group described observations made 
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between March 1985 and June 1987 and included a sample 
size of only 60 patients; the data analysis was restricted 
exclusively to treatment with propafenone. The present 
report provides data on nearly twice the number of patients 
with approximately 2 additional years of follow-up and 
includes the results of treatment with sotalol in addition to 
propafenone. 
Methods 
Study patients, Entry criteria. Between March 1985 and 
March 1989 patients referred from the medical services of 
the Brigham and Women’s Hospital, Beth Israel Hospital 
and Children’s Hospital Medical Center were evaluated for 
inclusion in the protocol. Entry criteria included: 1) age > 18 
years: 2) electrocardiographic (ECG) documentation of a 
history of atria1 fibrillation, atria1 flutter or an ECG hybrid of 
the two rhythms (atria1 flutter/fibrillation); 3) a past history of 
at least one unsuccessful previous trial of suppressive anti- 
arrhythmic therapy with one or more of the following 
conventional drugs: quinidine, procainamide or disopyra- 
mide (past therapy with these conventional agents was 
considered unsuccessful if atria1 fibrillation [or atria1 flutter, 
or both] recurred despite therapeutic doses or intolerable 
drug-related side effects occurred necessitating discontinua- 
tion of the drug regardless of the adequacy of arrhythmia 
suppression); and 4) clinical evidence that the development 
of atrial fibrillation or flutter was reproducibly associated 
with symptoms recognized by the patient, such as light- 
headedness, palpitation, dyspnea or syncope. 
Exclusion criteria. Patients were excluded from the study 
if one or more of the following conditions were present: 
1) acute myocardial infarction within 1 week of entry into the 
trial; 2) cardiogenic shock; 3) atria1 fibrillation or flutter, or 
both. that was transient resulting from an unresolved acute 
or subacute illness such as pneumonia, pulmonary embo- 
lism, recent cardiac surgery or uncontrolled congestive heart 
failure (patients with pericarditis were considered for inclu- 
sion in the trial only if they had a chronic relapsing form of 
the disease); 4) acutely deteriorating hepatic or renal func- 
tion; and 5) therapy with amiodarone within 12 months, 
provided maintenance therapy with amiodarone had been 
prescribed for ~1 month. Patients with left ventricular 
ejection fraction ~20% or a history of severe bronchospastic 
lung disease were excluded from treatment with sotalol (see 
below). 
Protocol design. The protocol consisted of open label 
drug trials with propafenone (stage 1) and sotalol (stage 2). 
All patients were initially treated with propafenone and only 
underwent a trial with sotalol after documented recurrence 
of atria1 fibrillation or flutter on a maximally tolerated dose of 
propafenone or when intolerable side effects developed 
necessitating discontinuation of the drug. Each drug trial 
consisted of three phases that were related to drug dosing: a 
Table 1. Dosage Schedule 
Dose Titration Maintenance 
Loading Dose Range Dose Range 
Stage Dmg (ma) (m&ray) (mg/day) 
I Propafenone 150-300 450-900 450-m 
2 Sotalol SO-160 160-960 160-960 
loading phase, a dose titration phase and a long-term main- 
tenance phase (Table 1). The order of the drug trials was 
designed to minimize exclusion because of poor left ventric- 
ular function or bronchospasm by selecting propafenone as 
the first drug. 
For both the propafenone and sotalol trials, all patients 
were hospitalized in an ECG telemetry ward during the 
loading phase and initial dose titration phase. Before patient 
entry into the protocol, all antiarrhythmic drugs were dis- 
continued. When clinically feasible, agents being used to 
control the ventricular rate (for example, digitalis glyco- 
sides, beta-adrenergic blocking agents, verapamil and dilt- 
iazem) were also discontinued to eliminate any confounding 
electrophysiologic effects that could interfere with interpre- 
tation of the impact of the study drugs. 
Before enrollment, 1111 patients u’ere classijied as having 
paroxysmal atria1 fibrillation or flutter or chronic atria1 
fibrillation or flutter on the basis of the predominant pattern 
exhibited by their arrhythmia in the preceding month. Indi- 
viduals whose arrhythmia was characterized by recurrent 
self-terminating episodes, usually no more than 24 to 48 h in 
duration and interspersed with long periods of sinus rhythm, 
were designated as having paroxysmal atria1 fibrillation. 
Patients in whom atria1 fibrillation or flutter was the predom- 
inant and chronic rhythm, and in whom sinus rhythm had 
only been observed transiently after previous attempts at 
electrical or pharmacologic cardioversion, were designated 
as having chronic atria1 fibrillation. 
Recent data (11-14) suggest that atriul fibrillation and 
atria1 jlutter may have c( common electrophysiologic mech- 
cmism, namely, reentry within the atria1 myocardium. Elec- 
trocardiographic patterns in individual patients frequently 
alternate spontaneously between atria1 fibrillation and atria1 
flutter or may appear as a hybrid of the two rhythms because 
they may coexist in different regions of the atria at the same 
time. No attempt was made during this trial to differentiate 
atrial fibrillation from atria1 flutter. In this report, the term 
atria1 fibrillation will signify both types of ECG patterns. 
Drug treatment schedule (Table 1). At the inception of 
each drug trial, written informed consent was obtained 
before the loading phase was initiated. All consent forms 
were approved by the Committee for the Protection of 
Human Subjects from Research Risks at the Brigham and 
Women’s Hospital. During the titration phase with pro- 
pafenone or sotalol, at least 48 to 72 h was allowed to elapse 
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between dose changes to permit steady state to be achieved. 
Upward dose titration with propafenone or sotalol took 
place over several days to weeks, depending on the clinical 
response. For patients with chronic atria1 fibrillation, pro- 
pafenone was increased to a maximum of 900 mg/day, and 
direct current cardioversion was performed in those individ- 
uals in whom sinus rhythm had not been restored pharma- 
cologically. In the case of sotalol, direct current cardiover- 
sion was performed in patients with chronic atria1 fibrillation 
when the daily dose had been titrated to 2320 mg. For 
patients with chronic atria1 fibrillation taking sotalol who 
subsequently had recurrent atria1 fibrillation after an initial 
successful cardioversion, one or more additional cardiover- 
sion procedures were performed as needed with higher 
doses. In patients with paroxysmal atria1 fibrillation treated 
with propafenone or sotalol, each time the arrhythmia re- 
curred the dose of the study drug was increased as tolerated 
to a maximum of 900 mg/day for propafenone and 960 
mg/day for sotalol. Thus, several recurrences of atria1 fibril- 
lation (while the patient was receiving incremental dosages 
of the drug) were permitted before a trial was considered 
unsuccessful. 
During each stage ofthp drug trial, the only indication for 
a downward adjustment in drug dose during the long-term 
maintenance phase was the appearance of drug-related side 
effects or the development of a rate-corrected QT interval 
20.5 s on the ECG, or both. Serum concentrations of the 
study drugs were not routinely measured and were not used 
to modify dosage schedules. The dose reported for each 
patient represents the highest tolerated dose of either pro- 
pafenone or sotalol during the long-term maintenance phase. 
Documentation of recurrence of arrhythmia and drug- 
related side effects. All patients and referring physicians 
were instructed to confirm any suspected recurrence of atria1 
fibrillation during the maintenance phase of each stage. This 
was accomplished by recording a 12 lead ECG, 24 h ambu- 
latory ECG or rhythm strip obtained by telemetry or tele- 
phone ECG transmitter. To maximize the probability of 
documenting atria1 fibrillation recurrence and to determine 
the number of months between the beginning of the mainte- 
nance phase and the recurrence of atria1 fibrillation, all 
patients were given a telephone ECG transmitter at the time 
of hospital discharge. To ensure that patients would have a 
transmitter available when they were at maximal risk (that 
is, the first few months after restoration of sinus rhythm), 
telephone transmitters were reassigned as needed from 
subjects who had been free of arrhythmia the longest (b3 to 
6 months). 
All patients were evaluated by one of the study physi- 
cians or a specially trained cardiovascular research nurse, or 
both, every 3 months for determination of cardiac rhythm 
and review of possible drug-related side effects. Whenever 
patients reported symptoms suggestive of recurrence of 
atria1 fibrillation, more frequent visits were arranged. The 
telephone ECG transmitter system was utilized not only for 
documentation of atria1 fibrillation recurrence, but also to 
maintain contact between the patient and study personnel 
and to ensure compliance with the protocol. 
Data collection, longitudinal follow-up evaluation and 
study termination. Before enrollment into the protocol, 
baseline demographic data were recorded, including all 
relevant cardiac diagnoses, echocardiographic examination 
for evaluation of underlying cardiac disease, measurement of 
left atria1 size and determination of left ventricular ejection 
fraction, and the number of months elapsed since the original 
ECG-documented diagnosis of atria1 fibrillation as deter- 
mined from medical records. Among patients with chronic 
atria1 fibrillation, the number of these undergoing pharmaco- 
logic conversion to sinus rhythm was noted for each stage. 
When direct current cardioversion was required to restore 
sinus rhythm, an energy titration technique was utilized to 
establish the minimal amount of energy needed to terminate 
atria1 fibrillation. 
All patients were followed up for the duration of the time 
they were receiving study medication. The primary end point 
of the trial was the duration of sinus rhythm at each stage as 
measured from the date of the most recent cardioversion 
procedure in the chronic atria1 fibrillation group and the date 
48 h after initiation of the final maintenance dose in the 
paroxysmal atria1 fibrillation group. At the time of the first 
ECG-documented symptomatic recurrence of atria1 fibrilla- 
tion or whenever intolerable drug-related side effects oc- 
curred that necessitated withdrawal of the drug, the current 
stage was considered to be unsuccessful and patients were 
advanced to the next stage of the protocol. 
Statistical analysis. Data analysis was performed on ob- 
servations made through March 1989. Patient response to 
treatment during each drug trial was classified into one of the 
following three categories: success (absence of recurrent 
atria1 fibrillation or intolerable side effects for the duration of 
follow-up), relapse (any recurrence of atria1 fibrillation dur- 
ing follow-up once sinus rhythm was established and the 
patient was in steady state on drug treatment) and failure 
(recurrence of atria1 fibrillation or intolerable side effects or 
both, during follow-up). For each patient entering the vari- 
ous stages of the protocol, the time to first recurrence of 
atria1 fibrillation or development of intolerable side effects 
was noted. These primary end point data were analyzed 
using the product limit method of Kaplan and Meier to 
construct actuarial estimates of the proportion of patients 
free of any symptomatic recurrences of atria1 fibrillation over 
time for each of the therapeutic stages (15,16). Patients who 
remained in sinus rhythm were excluded from the study 
when and if they were withdrawn from treatment because of 
intolerable side effects. Patients in the chronic atria1 fibrilla- 
tion category who could not be successfully converted to 
sinus rhythm with direct current shock were arbitrarily 
assigned a short follow-up time of 0.001 month for the 
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purpose of constructing the actuarial curves described. 
Actuarial curves were compared using the Mantel-Haenszel 
form of the log-rank test. In addition, the relapse rate (17) 
(hazard function) measured in events per patient-month was 
calculated for various monthly intervals for each stage of 
treatment using the following formula: 
Relapse rate = 
Number of patients experiencing a relapse of atria1 fibrillation 
Total observed follow-up time in patient-months during the interval 
For each stage of protocol, the average follow-up time in 
months was calculated as 
Average follow-up time = 
Sum of follow-up times for all patients entering stage 
Number of patients entering stage 
To estimate the success in maintaining sinus rhythm with 
our treatment program (consecutive treatments with pro- 
pafenone followed by sotalol [conditional on prior failure 
with propafenone]), a separate actuarial curve was con- 
structed. (This reflects our experience without resorting to 
alternative therapy.) The cumulative number of months free 
of treatment failure for this program was determined for each 
patient by assuming there was no delay in time from the 
point of failure during treatment with propafenone (stage 1) 
to enrollment in the sotalol trial (stage 2), treating the 
duration of follow-up for each patient free of failure in stage 
I or stage 2 as a censored event and utilizing the cumulative 
duration of follow-up on stage 1 plus stage 2 for all patients 
with an unsuccessful stage 1 who entered stage 2. 
The proportion of patients classijed as having chronic 
atria1 fibrillation who underwent pharmacologic conversion 
to sinus rhythm during the various stages was compared 
using a two tailed Fisher’s exact test. Assessment of corre- 
lates of response to treatment was restricted to atria1 fibril- 
lation pattern and left atria1 size because these two baseline 
variables have consistently been identified as important 
prognostic markers of patient response. Statistical signifi- 
cance was taken at p < 0.05 for all analyses. Data are 
reported as mean values 2 standard deviation unless other- 
wise indicated. 
Results 
Clinical characteristics of study group (Table 2). One 
hundred nine patients (70 men and 39 women) were enrolled 
in the trial. The scope of cardiac diagnoses was broad, but in 
11% of the group no structural organic heart disease was 
detected (idiopathic atria1 fibrillation). Fifty-three patients 
(49%) were classified as having chronic atria1 fibrillation and 
56 (51%) as having paroxysmal atria1 fibrillation. A median of 
24 months (range 0.3 to 576) had elapsed since atrial fibril- 
Table 2. Clinical Characteristics of the Study Group 
No. % 
Patients 109 M 64; F 36 
Age tyr) 63 lr 13” 
Months since AF Dx Median 24 (range 0.3 to 576) 
Cardiac Dx 
Hypertension 39 34 
Valvular 3’ _- 29 
CHF 29 27 
Other 29 27 
Idiopathic 12 I1 
Previous drug trials Median 2 (range I to 5) 
Quinidine 90 
Procainamide 63 
Disopyramide 28 
LA size (cm) 4.4 2 0.9* 
LV EF 51 + 14* 
Pattern: 
CAF 53 49 
PAF 56 51 
*Mean values 2 SD; tin month before trial entry. AF = atrial fibrillation; 
CAF = chronic atria1 fibrillation: CHF = congestive heart failure; Dx = 
diagnosis: EF = ejection fraction; F = female; LA = left atrial; LV = left 
ventricular; M = male: Other = sick sinus syndrome (SSS), pericardial or 
pulmonary disease, post coronary bypass graft surgery ICABG); PAF = 
paroxysmal atrial fibrillation. 
lation was first documented on an ECG. The group had been 
unsuccessfully treated by a median of 2 previous drug 
programs (range 1 to 5). In the group of patients who had had 
an unsuccessful previous trial with quinidine (90% of pa- 
tients), that previous trial was considered unsuccessful be- 
cause of recurrence of atria1 fibrillation in 53% of cases, 
intolerable side effects in 45% of cases and both recurrence 
of atria1 fibrillation and intolerable side effects in 2% of 
cases. In the patients who had failed a previous trial of 
procainamide (63% of patients), that previous trial was 
considered unsuccessful because of recurrence of atria1 
fibrillation in 54% and intolerable side effects in 46%. 
The median left atria1 anteroposterior dimension for the 
group was 4.5 cm (range 3.0 to 7.5, mean 4.4). Fifty-two 
individuals (48%) who had a left atria1 dimension ~4.5 cm 
were designated the large left atria1 group; the 57 individuals 
(52%) with a left atria1 dimension c4.5 cm were designated 
the small left atria1 group. In the subset of patients with a 
paroxysmal atria1 fibrillation pattern, the mean number of 
arrhythmic events per month at 12, 6 and 1 month before 
trial entry was 5.9 + 13.5, 7.5 t_ 13.9 and 14.5 2 15.2, 
respectively. Of the 56 patients with paroxysmal atria1 
fibrillation, 28 (50%) had 210 episodes of atria1 fibrillation in 
the month before trial entry, and these individuals were 
designated the frequent paroxysmal atrialfibrillation group. 
The other 28 patients in the paroxysmal atria1 fibrillation 
group had ~10 episodes of atria1 fibrillation in the month 
before trial entry and were designated the infrequent parox- 
ysmal atria1 jibrillation group. 
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AF REFRACTORY TO CONVENTIONAL Rx 
FAILURE’ SUCCESS 
- 75 + PROPAFENONE *34 
791 t 176 MGIDAY 
I Alternative therapy for AF I 
Figure 1. Flowchart of 109 patients with atria1 fibrillation or flutter 
(AF) in two sequential drug trials, each stage being represented by 
a box. For each stage, the number of successes and failures is shown 
to the right and left of the boxes, respectively. The mean dosage of 
the drugs employed is recorded in each box. Patients with a left 
ventricular ejection fraction (LV E.F.) <20% or clinically significant 
chronic obstructive pulmonary disease (COPD), or both, were not 
eligible for treatment with sotalol and, therefore, were treated with 
alternative therapy (Rx) on failure of propafenone. *Failure = at 
least one recurrence of electrocardiograhically (ECG) documented 
atria1 fibrillation (AF) or intolerable side effects; Success = no 
recurrence of ECG-documented symptomatic atria1 fibrillation and 
no intolerable side effects. 
Response to sequential stages of antiarrhythmic therapy. 
All patients were followed up for the duration of treatment 
while still receiving one of the therapeutic regimens; none 
was lost to follow-up. Each stage of the two sequential drug 
trials is summarized in Figure 1. Three individuals who were 
ineligible for sotalol treatment bypassed stage 2 and pro- 
ceeded to alternative therapy after failure of stage 1. Not all 
patients with an unsuccessful propafenone trial advanced to 
the sotalol trial because of one or more of the following 
circumstances: patient refusal, nondrug-related death or 
failure to enter the next stage by the time of the data 
analysis. Eighty-five (78%) of the 109 patients followed the 
prescribed course of progressive advancement to sotalol 
after recurrence of atria1 fibrillation or the development of 
intolerable propafenone-related side effects. Of the 24 pa- 
tients (22%) who did not follow the prescribed course of 
therapy, 13 refused to adhere to the sequence of drug trials, 
4 died of nondrug-related causes and 7 had not started on 
therapy in the next stage at the time of data analysis. There 
were no significant differences between the group of 24 
patients who did not follow the full prescribed course and the 
group of 85 patients who did follow the course of treatment 
with regard to gender, age, number of months since original 
diagnosis of atria1 fibrillation, pattern of atria1 fibrillation in 
pretrial month, number of previous unsuccessful drug trials, 
left atria1 size and left ventricular ejection fraction. 
The average follow-up time and number of successfully 
treated patients for the sequence of drug trials were as 
follows: propafenone, 5.6 months (range 0.001 to 52.3), 34 of 
109 patients; and sotalol, 3.9 months (range 0.001 to 27.3), 26 
of 48 patients. Eight (8%) of the 97 instances of treatment 
failure during the two stages of the trial (sum of values on the 
left side of Fig. 1) were a result of intolerable side effects 
despite maintenance of sinus rhythm. 
Among the patients with chronic atrialfibrillation treated 
with propufenone in stage 1, 3 (6%) of 53 had spontaneous 
reversion to sinus rhythm. Among the remaining patients 
treated with propafenone, atria1 fibrillation was successfully 
terminated in all but one. A significantly greater proportion 
of the patients with chronic atria1 fibrillation (7 [27%] of 26) 
had spontaneous pharmacologic conversion to sinus rhythm 
with sotalol during stage 2, as compared with propafenone 
during stage 1 (p = 0.012). All but one patient with chronic 
atria1 fibrillation, who underwent direct current cardiover- 
sion in stage 2, also had restoration of sinus rhythm. The 
mean maintenance doses of antiarrhythmic medication dur- 
ing each of the stages of the protocol were 791 ? 176 mg/day 
for propafenone and 537 k 223 mg/day for sotalol (Fig. 1). 
Actuarial estimates of freedom from first symptomatic 
relapse of atrialjibrillation during each of the drug trials are 
compared in Figure 2. The curves show 1 year of follow-up 
data for all cases. By 6 months, approximately 39% of 
patients were free of recurrent atria1 fibrillation while receiv- 
ing propafenone (stage 1) as were 50% while receiving 
sotalol (stage 2). At each stage, clinical responses tended to 
remain relatively constant beyond 6 months. Because of the 
reduced number of patients followed up during propafenone 
and sotalol therapy after 12 months, estimates of the efficacy 
of these drugs after 2 1 year of therapy have wide confidence 
intervals. In each of the two trials, the atria1 fibrillation 
recurrence rate was consistently highest during the first 
month of maintenance therapy; the first month recurrence 
rates were not significantly different between the two treat- 
ment strategies. Only infrequent late recurrences were noted 
during the remaining 9 months of the first year of follow-up 
(Fig. 2). 
Cumulative success of treatment before initiation of alter- 
native therapy and correlates of response to therapy. The 
cumulative proportion of patients successfully treated in the 
two drug trials is depicted in Figure 3. By 3 months, 59% of 
the total study group was still free of arrhythmia recurrence 
without resorting to alternative therapy. This proportion 
decreased slightly to 55% by 6 months and remained rela- 
tively constant beyond that point. The recurrence-free time 
curves (combining the first two stages) did not differ accord- 
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Figure 2. The two panels of this figure show the percent of patients 
free of symptomatic atria1 fibrillation (AF) for each stage (stage 1 
and stage 2) by time calculated according to Kaplan-Meier method 
(left vertical scale). The bar graph in the lower portion of each panel 
represents the estimated relapse rate or hazard function (right 
vertical scale) in relapses/patient-month, where each event repre- 
sents an individual patient experiencing a recurrence to atrial 
fibrillation over the interval of time analyzed. The intervals analyzed 
included every month for the first 3 months and then 3 month blocks 
for the remaining 9 months of the first year. A rate of one 
relapse/patient-month corresponds to 23 relapses/l00 patients per 
week. The number of patients at each time interval is listed at the 
bottom. 
stage 1 
-0 1 2 3 4 5 6 7 8 9 10 11 12 
Months on Propafenone 
109 53 43 36 36 32 30 26 26 27 26 24 22 
Number at risk 
stage 2 
r lo 
0 1 2 3 4 5 6 7 8 9 10 11 12 
Months on Sotalol 
4s 21 17 14 13 12 12 11 9 9 9 0 7 
Number at risk 
80 
1 
10 i 
o!.,.,.,.,.,.,.,,,.,.,.,., 
012345678 9 10 11 12 
Months on Treatment 
109 66 57 51 46 44 42 36 37 35 34 32 30 
Number at risk 
Figure 3. Actuarial curve depicting the proportion of patients who at 
analysis were free of symptomatic atria1 fibrillation and in stage 1 or 
stage 2. For example, at 6 months, 55% of patients were free of 
symptomatic atrial fibrillation and in either stage 1 or stage 2. The 
number of patients at each time interval is listed at the bottom. 
ing to patient subgroups classified by size of left atrium 
(small [median time to relapse of atria1 fibrillation 4.1 
months] versus large [median time to relapse of atria1 fibril- 
lation 4.2 months]), pattern of atria1 fibrillation in the month 
before trial entry (chronic versus paroxysmal atria1 fibrilla- 
tion) and the number of episodes of atria1 fibrillation in the 
month before trial entry (< 10 versus I 10 episodes). Further- 
more, there were no detectable interactions among these 
factors. 
Tolerability of long-term antiarrbythmic therapy (Table 3). 
Drug-related adverse reactions were seen in approximately 
29% of patients. The majority of events were noncardiovas- 
cular, with neurologic disturbances (ataxia, dizziness, head- 
ache, blurred vision, fatigue) being the most common. Treat- 
ment with propafenone was associated with gastrointestinal 
complaints (constipation, epigastric discomfort) and a me- 
tallic taste in 13% and 7% of patients, respectively. Although 
a reduction in the heart rate at rest was common with sotalol, 
only 10% of patients developed symptomatic bradycardia, 
which in one case required insertion of a permanent dual 
chamber pacemaker to permit continued administration of 
the drug. Exacerbation of congestive heart failure was 
uncommon in both drug trials. No clinically significant 
deterioration in renal function developed during the course 
of the study protocol. One patient developed abnormal liver 
function tests after ~2 months of therapy with propafenone; 
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Table 3. Drug-Related Side Effects 
Side Effect 
Cardiovascular (%) 
Bradycardia 
CHF 
Edema 
Raynaud’s 
VTNF 
Exacerbation of AF 
Noncardiovascular (%) 
CNS 
GI 
Impotence 
Taste 
Drug-related death (%) 
With ~1 side effect (%) 
Drug stopped because of 
side effects (%) 
Propafenone Sotalol 
Stage 1 Stage 2 
(n = 109) (n = 48) 
3 IO 
3 2 
0 2 
0 2 
1 2 
0 0 
10 19 
13 0 
0 2 
7 0 
0 0 
28 29 
7 8 
CNS = central nervous system; GI = gastrointestinal; VTNF = ventric- 
ular tachycardia/fibrillation; other abbreviations as in Table 2. 
these normalized after cessation of the drug. One patient 
developed new onset of nonsustained ventricular tachycar- 
dia while receiving 900 mg/day of propafenone, which was 
no longer observed when the dose was reduced to 600 
mg/day. One patient developed nonsustained torsade de 
pointes ventricular tachycardia during treatment with 560 
mg/day of sotalol, necessitating discontinuation of that drug 
because lower doses of sotalol had not prevented recur- 
rences of atria1 fibrillation. No patient died of drug-related 
causes. Despite the development of drug-related side effects 
in approximately 1 in 4 patients during the course of the 
study, only 7% to 8% of patients (approximately 1 in 10) 
required termination of a stage of antiarrhythmic therapy 
because of intolerable adverse reactions. 
Discussion 
Although sinus rhythm can be restored at least transiently 
in the overwhelming majority of patients with atria1 fibrilla- 
tion by direct current cardioversion, the recurrence rate is 
high when no suppressive antiarrhythmic therapy is admin- 
istered. It is estimated that only 15% to 40% of patients 
remain in sinus rhythm by 6 months after cardioversion; 
substantially fewer will be in sinus rhythm by the end of 1 
year (18-28). Quinidine is still commonly regarded as the 
drug of choice for initial attempts at suppression of recurrent 
atria1 fibrillation. However, data available from previous 
studies (19) suggest that only about 50% to 60% of quinidine- 
treated patients remain in sinus rhythm by 6 to 12 months. Of 
note, trials that provide estimates of quinidine’s effective- 
ness often excluded patients with an enlarged left atrium, 
lengthy history of atria1 fibrillation or a history of intolerance 
to quinidine preparations. Perhaps of even greater clinical 
relevance is the fact that quinidine preparations provoke 
adverse reactions in as many as 30% to 60% of patients and 
are often implicated in drug-induced episodes of ventricular 
proarrhythmia and sudden cardiac death, particularly in the 
presence of atria1 fibrillation (29-3 1). 
Major findings of the present trial. The present study 
suggests that propafenone and sotalol offer important thera- 
peutic alternatives to quinidine. Despite a history of several 
unsuccessful drug trials with conventional type IA agents, 
including quinidine, a significant proportion of patients with 
recurrent symptomatic atria1 fibrillation in this study could 
be treated successfully with new antiarrhythmic agents; 
approximately 55% were successfully treated for at least 6 
months with sequential trials of propafenone and sotalol 
without having to resort to amiodarone therapy. Therapy 
with propafenone and sotalol was associated with a rela- 
tively low incidence of intolerable side effects which com- 
pares favorably with reported experience with quinidine 
preparations (29,30). Of interest was the observation that left 
atria1 enlargement and a history of long-standing atria1 fibril- 
lation did not adversely affect the likelihood of successful 
treatment with propafenone and sotalol. This is in contrast to 
previous studies with quinidine in which these factors were 
predictive of poor outcome (21,23,26). 
Approximately 25% of patients with chronic atria1 fibril- 
lation underwent spontaneous pharmacologic conversion to 
sinus rhythm during loading with sotalol. Although higher 
pharmacologic conversion rates have been reported (32-35) 
with high doses of quinidine (1 to 2 g orally over 5 to 10 h), 
this treatment was supplanted by direct current cardiover- 
sion because of an unacceptably high rate of side effects. The 
doses of quinidine currently employed in clinical practice 
have not been reported to achieve pharmacologic conversion 
rates as high as that seen for sotalol in this study (18). 
For both drug trials, the relapse rate was highest during 
the jirst 3 months and then decreased sharply for the 
remainder of the first year of therapy. A similar pattern of an 
early high relapse rate has been reported with virtually every 
other trial of suppressive antiarrhythmic agent for atria1 
fibrillation regardless of agent employed (3,22,23,25). This 
pattern allows early identification of most patients who fail 
to be adequately treated with a given drug, enabling them to 
undergo trials with other agents without undue delay. 
Our results should be viewed in the context of the nature 
of the patients’ condition in the present trial. Although 
typical of the usual spectrum of clinical cardiology practice, 
the patients studied were selected by virtue of a history of 
failure of at least one trial with a type IA antiarrhythmic 
agent, a history of recurrent atria1 fibrillation that was 
reliably associated with symptoms and, in most cases, well 
preserved left ventricular function. Individuals with an en- 
larged left atrium or a long history of symptomatic arrhyth- 
mia were not specifically excluded. Compared with enroll- 
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ment criteria of previously published studies of conventional 
drugs (21-26), the criteria in the present investigation welt: 
less restrictive and, therefore, should have biased our pa- 
tient selection toward patients expected to be particularly 
refractory to suppressive antiarrhythmic therapy. Thus, the 
cumulative success in 55% of patients at the end of 6 months 
before trials of alternative therapy, coupled with the obser- 
vation that nearly 90% of patients are free of intolerable 
drug-related adverse reactions, should be regarded as en- 
couraging. 
Although 24 patients (22% of the study group) did not 
follow the prescribed course of progression to successive 
stages conditional on failure of preceding stages, it is un- 
likely that the results would have been altered in any 
noteworthy manner if 100% of the study group followed the 
full protocol. The lack of any significant difference in base- 
line characteristics between those individuals who did and 
did not follow the full protocol suggests that the observed 
response rates were representative of the entire study group. 
Possible mechanisms of antiarrbytbmic drug effect. The 
precise electrophysiologic mechanisms by which antlar- 
rhythmic agents exert their beneficial effects in suppressing 
atria1 fibrillation in humans remain speculative. On the basib 
of the leading circle theory of atria1 reentry and atrial 
fibrillation (11,36), antiarrhythmic drugs that result in a 
lengthening of the wavelength of a reentrant circuit should 
have antifibrillatory potential. Because wavelength is the 
product of conduction velocity times refractory period and 
because type III antiarrhythmic drugs such as sotalol have 
limited effect on conduction velocity in atria1 tissue, It is 
likely that whatever beneficial effect these drugs have in 
suppressing atria1 fibrillation stems from their ability to 
prolong the atria1 effective refractory period (8). The bene- 
ficial effect of a type IC drug (such as propafenone) in 
suppressing atria1 fibrillation is more difficult to explain 
because the principal effect of this drug is to slow conduction 
velocity, an effect that should cdusc a decrease rather than 
an increase in wavelength. It may be that because of the high 
drive rates of atria1 fibrillation, propafenone causes a marked 
frequency-dependent decrease in atria1 conduction velocity 
and that subsequent decremental conduction and extinction 
of circulating wave fronts is the mechanism by which this 
drug suppresses atria1 fibrillation (37). As predicted by the 
work of Allessie and coworkers (11,36), prolongation of the 
atria1 effective refractory period should be of greater unpor- 
tance than alteration of conduction velocity in preventing 
atria1 fibrillation. Data from the present study support this 
hypothesis because many patients who failed to be ade- 
quately controlled with propafenone were controlled by 
sotalol. Furthermore, the rate of pharmacologic conver>ion 
to sinus rhythm was higher with sotalol than with pro- 
pafenone. However, the nonrandomired nature uf the se- 
quence of therapies precludes definitive assessment of this 
hypothesis. 
Metbodologic considerations. Any study designed to eval- 
uate the efficacy of treatment for atrlal fibrillation must 
address a number of methodologic problems. Critically 
important among these is the problem of documenting car- 
diac rhythm before and after treatment. In the present trial, 
efficacy uf drug therapy was assessed chiefly by a reduction 
in symptomatic recurrence of atria1 fibrillation. Because both 
agents employed in this trial were capable of slowing the 
ventricular rate during atria1 fibrillation, they may have 
caused some patients to be asymptomatic during recurrence 
of atria1 fibrillation although they had been symptomatic 
before 01 during treatment with a dtug used m an earlier 
stage. In contrast, documentation of all recurrences of atria1 
fibrillation, both symptomatic and asymptomatic, would 
have requited continuous ECG monitoring for the entire 
follow-up period. Because of the expense and inconvenience 
involved, such an approach is impractical and unlikely to be 
implemented in a clinical trial. To enhance the detection of 
recurrent symptomatic episodes of atria1 fibrillation in the 
present trial. we utilized telephone ECG transmitters, which 
obvidtcd the need to obtain a 12 lead ECG or long-term 
ambulatory KG in many patients (38). The telephone ECG 
system also afforded the opportunity to detect some asymp- 
tomatic recurrences during routine telephone transmissions. 
Of th,: 89 mstances of a relapse of atria1 fibrillation during the 
two stages of the trial, only 7 (8%) were aaymptomatic; 3 of 
these were detected by telephone EKG and 4 were detected 
dt Ioutine ofice visits. Of these seven asymptomatic recur- 
lences, only one occurred beyond 6 months. If we had not 
utilized the telephone ECG system, some of the asympto- 
matic recurrences would not have been diagnosed as 
promptly or at all. This would mean that our success rates 
would h&e been higher and the times to diagnosis of relapse 
of atria1 fibrillation longer. Nevertheless, based on these 
detection rates of asymptomatic recurrences, our calcula- 
tions of relapse rates may have underestimated the number 
of recurrences by about 10%. This would have reduced the 
proportion of successfully treated patients from the ob- 
served 55% to approximately 50% at 6 months. 
Another methodologic problem any study of drug efficacy 
for suppression of atria1 fibrillation must address is whether 
to use as an end point the number of relapses of atrial 
fibrillation during a period of observation or the time to first 
relapse of atria1 fibrillation (39,40). Utilization of each pa- 
tient as his or her own control requires comparison of 
pretrial relapse rate measurements with those obtained dur- 
ing therapy. This would have been suitable for patients with 
paroxysmal atria1 fibrillation who do not require multiple 
cardioversions to restore sinus rhythm, but not for those 
with chronic atria1 fibrillation. Because data on the details of 
previous unsuccessful therapy with type IA antiarrhythmic 
drugs were limited (especially in the chronic atria1 fibrillation 
group), the fact that both patients with chronic or paroxys- 
mal atria1 fibrillation were enrolled and because of our desire 
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to apply the same measurement technique to both those 
with chronic or paroxysmal atria1 fibrillation, we chose to 
monitor the time to first relapse (that is, arrhythmia-free 
interval). This approach had the additional advantages of 
not delaying treatment in symptomatic patients while pre- 
trial observations were made and permitting assessment of 
multiple drugs in a short time interval when failures oc- 
curred. It should be pointed out, however, that such an 
approach did not permit strict comparison between the 
elaborate dosing and titration scheme utilized with the study 
drugs and the pretreatment therapy that had been deemed 
ineffective. 
Clinical implications. Studies without internal controls 
such as the present one cannot form the basis of definitive 
therapeutic recommendations. However, they can provide 
useful information on current developments in medicine, 
pointing out important questions that can best be answered 
by randomized clinical trials. As outlined by Bailar et al. 
(41), observations made in studies relying on external con- 
trols, such as a previously described standard treatment, are 
considerably strengthened if such studies have five specific 
design features. All of these features can be found in the 
present study. The first feature is the likelihood that the 
intervention being applied will affect the outcomes reported 
or, in the present study, that better therapy for atria1 
fibrillation will be identified. Second, analysis of the results 
must be planned before generation of data. Our predeter- 
mined end point was measurement of the arrhythmia-free 
interval as analyzed by the life table method. Third, a 
plausible rationale must exist for interpretation of the data, 
such as the hypothesis that the electrophysiologic and phar- 
macologic profile of type IC and type III antiarrhythmic 
agents differs significantly from type IA agents. Fourth, the 
findings would be of interest even if “opposite” results had 
been obtained (for example, new drugs are less rather than 
more effective compared with standard treatment). Finally, 
there should be reasonable grounds for generalization of the 
results. In the present study, although the group of patients 
enrolled met a number of selection criteria, they were 
generally representative of patients commonly encountered 
in clinical cardiology practice. Based on the strength of the 
observations made in the present trial, it is clear that 
randomized clinical trials are now needed to determine 
whether new drugs such as those studied in this trial should 
be reserved for patients with refractory atria1 fibrillation or 
should be offered as initial therapy. 
We thank Marvin Zelen, PhD, Harvard School of Public Health, Boston, 
Massachusetts for his invaluable advice and assistance in the statistical 
analysis of this trial. 
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